Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status

Katharina L. Van Santen, Robert A. Bednarczyk, Dzifa Adjaye-Gbewonyo, Walter A. Orenstein, Robert Davis, Saad B. Omer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND: Influenza virus infection can predispose patients to secondary pneumococcal infections. Children are at greatest risk for pneumococcal infection in the first year of life and are not considered fully protected by pneumococcal conjugate vaccine (PCV) until their third dose at 6 months of age. Infants less than 6 months cannot receive influenza vaccination, though maternal influenza vaccination can protect infants. METHODS: We conducted a retrospective cohort study of 9807 mother-infant pairs enrolled in a managed care organization for infants born June 1, 2002, to December 31, 2009. Exposure was assessed for receipt of infant PCV only and the combination of PCV and maternal influenza vaccine (trivalent inactivated vaccine). Outcomes of interest were acute otitis media and medically attended acute respiratory infection in the first year of life. We estimated the adjusted incidence of illness, incidence rate ratios and vaccine effectiveness using the ratio of incidence rate ratios between the periods of noncirculating influenza and that of at least local influenza circulation. RESULTS: For medically attended acute respiratory infection, vaccine effectiveness for the combination of trivalent inactivated vaccine and PCV was 39.6% (95% confidence interval [CI]: 31.6%-46.7%) and for PCV only was 29.8% (95% CI: 11.4%-44.3%). For acute otitis media, vaccine effectiveness for the combination of trivalent inactivated vaccine and PCV was 47.9% (95% CI: 42%-53.3%) and for PCV only was 37.6% (95% CI: 23.1%-49.4%). CONCLUSION: In infants, the combination of maternal influenza vaccine and infant pneumococcal conjugate vaccination confers greater protection from acute otitis media infections and medically attended acute respiratory infections than does PCV alone.

Original languageEnglish (US)
Pages (from-to)1180-1184
Number of pages5
JournalPediatric Infectious Disease Journal
Volume32
Issue number11
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Human Influenza
Vaccination
Mothers
Inactivated Vaccines
Otitis Media
Respiratory Tract Infections
Confidence Intervals
Combined Vaccines
Pneumococcal Infections
Influenza Vaccines
Incidence
Managed Care Programs
Virus Diseases
Orthomyxoviridae
Coinfection
Cohort Studies
Vaccines
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status. / Van Santen, Katharina L.; Bednarczyk, Robert A.; Adjaye-Gbewonyo, Dzifa; Orenstein, Walter A.; Davis, Robert; Omer, Saad B.

In: Pediatric Infectious Disease Journal, Vol. 32, No. 11, 01.11.2013, p. 1180-1184.

Research output: Contribution to journalArticle

Van Santen, Katharina L. ; Bednarczyk, Robert A. ; Adjaye-Gbewonyo, Dzifa ; Orenstein, Walter A. ; Davis, Robert ; Omer, Saad B. / Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status. In: Pediatric Infectious Disease Journal. 2013 ; Vol. 32, No. 11. pp. 1180-1184.
@article{da15879754b54b718fe45f9c95481f40,
title = "Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status",
abstract = "BACKGROUND: Influenza virus infection can predispose patients to secondary pneumococcal infections. Children are at greatest risk for pneumococcal infection in the first year of life and are not considered fully protected by pneumococcal conjugate vaccine (PCV) until their third dose at 6 months of age. Infants less than 6 months cannot receive influenza vaccination, though maternal influenza vaccination can protect infants. METHODS: We conducted a retrospective cohort study of 9807 mother-infant pairs enrolled in a managed care organization for infants born June 1, 2002, to December 31, 2009. Exposure was assessed for receipt of infant PCV only and the combination of PCV and maternal influenza vaccine (trivalent inactivated vaccine). Outcomes of interest were acute otitis media and medically attended acute respiratory infection in the first year of life. We estimated the adjusted incidence of illness, incidence rate ratios and vaccine effectiveness using the ratio of incidence rate ratios between the periods of noncirculating influenza and that of at least local influenza circulation. RESULTS: For medically attended acute respiratory infection, vaccine effectiveness for the combination of trivalent inactivated vaccine and PCV was 39.6{\%} (95{\%} confidence interval [CI]: 31.6{\%}-46.7{\%}) and for PCV only was 29.8{\%} (95{\%} CI: 11.4{\%}-44.3{\%}). For acute otitis media, vaccine effectiveness for the combination of trivalent inactivated vaccine and PCV was 47.9{\%} (95{\%} CI: 42{\%}-53.3{\%}) and for PCV only was 37.6{\%} (95{\%} CI: 23.1{\%}-49.4{\%}). CONCLUSION: In infants, the combination of maternal influenza vaccine and infant pneumococcal conjugate vaccination confers greater protection from acute otitis media infections and medically attended acute respiratory infections than does PCV alone.",
author = "{Van Santen}, {Katharina L.} and Bednarczyk, {Robert A.} and Dzifa Adjaye-Gbewonyo and Orenstein, {Walter A.} and Robert Davis and Omer, {Saad B.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1097/INF.0b013e3182a26752",
language = "English (US)",
volume = "32",
pages = "1180--1184",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status

AU - Van Santen, Katharina L.

AU - Bednarczyk, Robert A.

AU - Adjaye-Gbewonyo, Dzifa

AU - Orenstein, Walter A.

AU - Davis, Robert

AU - Omer, Saad B.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - BACKGROUND: Influenza virus infection can predispose patients to secondary pneumococcal infections. Children are at greatest risk for pneumococcal infection in the first year of life and are not considered fully protected by pneumococcal conjugate vaccine (PCV) until their third dose at 6 months of age. Infants less than 6 months cannot receive influenza vaccination, though maternal influenza vaccination can protect infants. METHODS: We conducted a retrospective cohort study of 9807 mother-infant pairs enrolled in a managed care organization for infants born June 1, 2002, to December 31, 2009. Exposure was assessed for receipt of infant PCV only and the combination of PCV and maternal influenza vaccine (trivalent inactivated vaccine). Outcomes of interest were acute otitis media and medically attended acute respiratory infection in the first year of life. We estimated the adjusted incidence of illness, incidence rate ratios and vaccine effectiveness using the ratio of incidence rate ratios between the periods of noncirculating influenza and that of at least local influenza circulation. RESULTS: For medically attended acute respiratory infection, vaccine effectiveness for the combination of trivalent inactivated vaccine and PCV was 39.6% (95% confidence interval [CI]: 31.6%-46.7%) and for PCV only was 29.8% (95% CI: 11.4%-44.3%). For acute otitis media, vaccine effectiveness for the combination of trivalent inactivated vaccine and PCV was 47.9% (95% CI: 42%-53.3%) and for PCV only was 37.6% (95% CI: 23.1%-49.4%). CONCLUSION: In infants, the combination of maternal influenza vaccine and infant pneumococcal conjugate vaccination confers greater protection from acute otitis media infections and medically attended acute respiratory infections than does PCV alone.

AB - BACKGROUND: Influenza virus infection can predispose patients to secondary pneumococcal infections. Children are at greatest risk for pneumococcal infection in the first year of life and are not considered fully protected by pneumococcal conjugate vaccine (PCV) until their third dose at 6 months of age. Infants less than 6 months cannot receive influenza vaccination, though maternal influenza vaccination can protect infants. METHODS: We conducted a retrospective cohort study of 9807 mother-infant pairs enrolled in a managed care organization for infants born June 1, 2002, to December 31, 2009. Exposure was assessed for receipt of infant PCV only and the combination of PCV and maternal influenza vaccine (trivalent inactivated vaccine). Outcomes of interest were acute otitis media and medically attended acute respiratory infection in the first year of life. We estimated the adjusted incidence of illness, incidence rate ratios and vaccine effectiveness using the ratio of incidence rate ratios between the periods of noncirculating influenza and that of at least local influenza circulation. RESULTS: For medically attended acute respiratory infection, vaccine effectiveness for the combination of trivalent inactivated vaccine and PCV was 39.6% (95% confidence interval [CI]: 31.6%-46.7%) and for PCV only was 29.8% (95% CI: 11.4%-44.3%). For acute otitis media, vaccine effectiveness for the combination of trivalent inactivated vaccine and PCV was 47.9% (95% CI: 42%-53.3%) and for PCV only was 37.6% (95% CI: 23.1%-49.4%). CONCLUSION: In infants, the combination of maternal influenza vaccine and infant pneumococcal conjugate vaccination confers greater protection from acute otitis media infections and medically attended acute respiratory infections than does PCV alone.

UR - http://www.scopus.com/inward/record.url?scp=84886950160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886950160&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e3182a26752

DO - 10.1097/INF.0b013e3182a26752

M3 - Article

C2 - 23856786

AN - SCOPUS:84886950160

VL - 32

SP - 1180

EP - 1184

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 11

ER -